This is a correction to: Simone Cosima Boedecker-Lips and others, Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus, Rheumatology, Volume 62, Issue 3, March 2023, Pages e34–e35, https://doi.org/10.1093/rheumatology/keac459
In the originally published version of this manuscript, in Table 1, the first line under “vaccine type” should begin “AstraZeneca” instead of the value “10(11%)”. The value “10(11%) should be placed under column “BEL, n=88”. The value from the “overall” column was also missing (“12 (8.2%”). Table 1 should read:
Table 1.
SARS-CoV-2 vaccines, number of vaccinations, intervals between vaccinations, and anti-SARS-CoV-2 antibody levels
| Vaccination | Overall, n = 147 | BEL, n = 88 | no BEL, n = 59 | P-value |
|---|---|---|---|---|
| Vaccine type | 0.2 | |||
| AstraZeneca | 12 (8.2%) | 10 (11%) | 2 (3.4%) | |
| Biontech | 116 (79%) | 66 (75%) | 50 (85%) | |
| Moderna | 19 (13%) | 12 (14%) | 7 (12%) | |
| No. of vaccinations | >0.9 | |||
| 2 | 5 (10%) | 3 (10%) | 2 (10%) | |
| 3 | 43 (86%) | 26 (87%) | 17 (85%) | |
| Days between 1st and 2nd shot | 42 (33, 56) | 41 (36, 50) | 42 (31, 61) | 0.7 |
| Anti-SARS-CoV-2 IgG after second shot (AU/ml) | 812 (130, 5358) | 265 (91, 5410) | 3382 (1152, 5061) | 0.078 |
| Days between 2nd and 3rd shot | 194 (168, 215) | 196 (182, 220) | 186 (158, 214) | 0.4 |
| Anti-SARS-CoV-2 IgG after third shot (AU/ml) | 3405 (1386, 11 032) | 2657 (906, 5382) | 6258 (3010, 12 858) | 0.12 |
Days and antibody levels are given as medians with interquartile ranges. Statistical significance between the BEL and no-BEL groups was assessed by Wilcoxon rank sum exact test.
instead of:
Table 1.
SARS-CoV-2 vaccines, number of vaccinations, intervals between vaccinations, and anti-SARS-CoV-2 antibody levelsAstraZeneca12 (8.2%)
| Vaccination | Overall, n = 147 | BEL, n = 88 | no BEL, n = 59 | P-value |
|---|---|---|---|---|
| Vaccine type | 0.2 | |||
| 10 (11%) | 2 (3.4%) | |||
| Biontech | 116 (79%) | 66 (75%) | 50 (85%) | |
| Moderna | 19 (13%) | 12 (14%) | 7 (12%) | |
| No. of vaccinations | >0.9 | |||
| 2 | 5 (10%) | 3 (10%) | 2 (10%) | |
| 3 | 43 (86%) | 26 (87%) | 17 (85%) | |
| Days between 1st and 2nd shot | 42 (33, 56) | 41 (36, 50) | 42 (31, 61) | 0.7 |
| Anti-SARS-CoV-2 IgG after second shot (AU/ml) | 812 (130, 5358) | 265 (91, 5410) | 3382 (1152, 5061) | 0.078 |
| Days between 2nd and 3rd shot | 194 (168, 215) | 196 (182, 220) | 186 (158, 214) | 0.4 |
| Anti-SARS-CoV-2 IgG after third shot (AU/ml) | 3405 (1386, 11 032) | 2657 (906, 5382) | 6258 (3010, 12 858) | 0.12 |
Days and antibody levels are given as medians with interquartile ranges. Statistical significance between the BEL and no-BEL groups was assessed by Wilcoxon rank sum exact test.
These errors have been corrected in the article.